ES2527608T3 - Composición farmacéutica que contiene un vehículo de oxígeno estable a temperatura elevada - Google Patents
Composición farmacéutica que contiene un vehículo de oxígeno estable a temperatura elevada Download PDFInfo
- Publication number
- ES2527608T3 ES2527608T3 ES11746429.7T ES11746429T ES2527608T3 ES 2527608 T3 ES2527608 T3 ES 2527608T3 ES 11746429 T ES11746429 T ES 11746429T ES 2527608 T3 ES2527608 T3 ES 2527608T3
- Authority
- ES
- Spain
- Prior art keywords
- hemoglobin
- low
- erythrocytes
- remove
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title abstract 3
- 229910052760 oxygen Inorganic materials 0.000 title abstract 3
- 239000001301 oxygen Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 108010054147 Hemoglobins Proteins 0.000 abstract 24
- 102000001554 Hemoglobins Human genes 0.000 abstract 24
- 210000003743 erythrocyte Anatomy 0.000 abstract 9
- 239000012535 impurity Substances 0.000 abstract 8
- 235000018102 proteins Nutrition 0.000 abstract 5
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 239000000539 dimer Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 150000003573 thiols Chemical group 0.000 abstract 4
- 239000006166 lysate Substances 0.000 abstract 3
- 238000000108 ultra-filtration Methods 0.000 abstract 3
- INZBQWPDNWVYFR-OWOJBTEDSA-N 3,5-dibromo-2-[(e)-4-(2,4-dibromo-6-carboxyphenoxy)-4-oxobut-2-enoyl]oxybenzoic acid Chemical compound OC(=O)C1=CC(Br)=CC(Br)=C1OC(=O)\C=C\C(=O)OC1=C(Br)C=C(Br)C=C1C(O)=O INZBQWPDNWVYFR-OWOJBTEDSA-N 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 230000009089 cytolysis Effects 0.000 abstract 2
- 150000003904 phospholipids Chemical class 0.000 abstract 2
- 239000002699 waste material Substances 0.000 abstract 2
- 101000856264 Anadara inaequivalvis Globin-1 Proteins 0.000 abstract 1
- 102000004506 Blood Proteins Human genes 0.000 abstract 1
- 108010017384 Blood Proteins Proteins 0.000 abstract 1
- 206010057248 Cell death Diseases 0.000 abstract 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract 1
- 108010061951 Methemoglobin Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 229960004308 acetylcysteine Drugs 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 238000004440 column chromatography Methods 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 210000003038 endothelium Anatomy 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 230000002934 lysing effect Effects 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002040 relaxant effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000003774 sulfhydryl reagent Substances 0.000 abstract 1
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Método para la preparación de una composición farmacéutica que contiene un vehículo de oxígeno altamente purificada y estable a temperatura elevada, incluyendo la composición farmacéutica que contiene un vehículo de oxígeno hemoglobina tetramérica reticulada no polimérica, y comprendiendo el método las etapas siguientes: a) proporcionar sangre completa de mamífero que incluye al menos eritrocitos y plasma; b) separar los eritrocitos del plasma en la sangre completa de mamífero; c) filtrar los eritrocitos que se separaron del plasma para obtener una fracción de eritrocitos filtrados; d) lavar la fracción de eritrocitos filtrados para eliminar las impurezas proteínicas plasmáticas, dando como resultado eritrocitos lavados; e) disgregar los eritrocitos lavados mediante una lisis hipotónica controlada durante un tiempo suficiente para lisar los eritrocitos sin lisar los leucocitos en un aparato de citólisis instantánea a un caudal de 50-1000 litro/h para crear una disolución que comprende un lisado de eritrocitos disgregados; f) llevar a cabo una filtración para eliminar al menos una porción del retenido de desecho del lisado; g) extraer una primera disolución de hemoglobina del lisado; h) llevar a cabo un primer procedimiento de ultrafiltración utilizando un filtro de ultrafiltración configurado para eliminar las impurezas que presentan un peso molecular mayor que la hemoglobina tetramérica para eliminar además cualquier virus y retenido de desecho residual de la primera disolución de hemoglobina para obtener una segunda disolución de hemoglobina; i) llevar a cabo una cromatografía en columna de flujo continuo sobre la segunda disolución de hemoglobina para eliminar los fosfolípidos, las impurezas proteínicas y la hemoglobina dimérica y para formar una disolución de hemoglobina exenta de fosfolípidos, baja en impurezas proteínicas y baja en dímeros; j) llevar a cabo un segundo procedimiento de ultrafiltración sobre la disolución de hemoglobina exenta de fosfolípidos, baja en impurezas proteínicas y baja en dímeros utilizando un filtro configurado para eliminar las impurezas, dando como resultado una disolución de hemoglobina purificada concentrada exenta de fosfolípidos, baja en impurezas proteínicas y baja en dímeros; k) bloquear los grupos sulfhidrilo de las moléculas de hemoglobina en la disolución de hemoglobina purificada concentrada exenta de fosfolípidos baja en impurezas proteínicas y baja en dímeros mediante un reactivo de sulfhidrilo en un entorno completamente oxigenado de manera que las moléculas de hemoglobina presenten cada una al menos un resto de cisteína que incluye un grupo protector de tiol de manera que las moléculas de hemoglobina no puedan unirse al factor relajante derivado del endotelio en el sitio de cisteína; l) reticular la hemoglobina tiol protegida mediante fumarato de bis-3,5-dibromosalicilo (DBSF) con una relación molar de la hemoglobina tiol protegida a DBSF mayor que 1:2,5 a menor que 1:5,0 en un entorno desoxigenado para formar hemoglobina tetramérica reticulada estable a temperatura elevada sin la formación de hemoglobina polimérica, de manera que el peso molecular de la hemoglobina tetramérica reticulada resultante es 60-70 kDa y consiste esencialmente en hemoglobina tetramérica reticulada no polimérica; m) intercambiar un tampón fisiológico adecuado por la hemoglobina tetramérica reticulada; n) eliminar cualquier hemoglobina tetramérica no reticulada residual y cualesquiera sustancias químicas residuales mediante lavado; o) añadir N-acetilcisteína a una concentración de 0,2-0,4% a la hemoglobina tetramérica reticulada para mantener un nivel de metahemoglobina inferior a 5%; y p) añadir la hemoglobina tetramérica reticulada baja en dímeros, exenta de fosfolípidos, tiol protegida, estable a temperatura elevada hasta una temperatura de 80ºC, libre de hemoglobina polimérica, a un vehículo farmacéuticamente aceptable
Description
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US348764P | 2002-01-14 | ||
| US34876410P | 2010-05-27 | 2010-05-27 | |
| US13/013,847 US8742073B2 (en) | 2010-05-27 | 2011-01-26 | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
| US201113013847 | 2011-01-26 | ||
| US201113083639 | 2011-04-11 | ||
| US13/083,639 US7989593B1 (en) | 2010-05-27 | 2011-04-11 | Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof |
| PCT/US2011/032594 WO2011149602A1 (en) | 2010-05-27 | 2011-04-15 | High-temperature stable oxygen-carrier-containing pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2527608T3 true ES2527608T3 (es) | 2015-01-27 |
Family
ID=44314337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11746429.7T Active ES2527608T3 (es) | 2010-05-27 | 2011-04-15 | Composición farmacéutica que contiene un vehículo de oxígeno estable a temperatura elevada |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7989593B1 (es) |
| EP (1) | EP2411025B1 (es) |
| JP (1) | JP5261806B2 (es) |
| KR (1) | KR101185437B1 (es) |
| CN (2) | CN102405051B (es) |
| AR (1) | AR081222A1 (es) |
| AU (1) | AU2011221433B2 (es) |
| CA (1) | CA2752943C (es) |
| CY (1) | CY1115986T1 (es) |
| DK (1) | DK2411025T3 (es) |
| ES (1) | ES2527608T3 (es) |
| NZ (1) | NZ594915A (es) |
| PL (1) | PL2411025T3 (es) |
| PT (1) | PT2411025E (es) |
| RU (1) | RU2475252C1 (es) |
| SA (1) | SA111320476B1 (es) |
| SG (1) | SG182237A1 (es) |
| TW (1) | TWI377947B (es) |
| WO (1) | WO2011149602A1 (es) |
| ZA (1) | ZA201208726B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8048856B1 (en) * | 2010-06-23 | 2011-11-01 | Billion King, Ltd. | Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition |
| US8084581B1 (en) | 2011-04-29 | 2011-12-27 | Bing Lou Wong | Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus |
| US20130052232A1 (en) * | 2011-08-31 | 2013-02-28 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking |
| US9066933B2 (en) | 2011-09-06 | 2015-06-30 | Billion King International Ltd. | Oral delivery for hemoglobin based oxygen carriers |
| US20140106004A1 (en) * | 2012-10-12 | 2014-04-17 | Bing Lou Wong | Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence |
| CN103251998B (zh) * | 2012-11-08 | 2015-09-02 | 亿京国际有限公司 | 用于血红蛋白氧载体(hboc)溶液的精确输注递送系统 |
| ES2886531T3 (es) | 2013-01-07 | 2021-12-20 | Omniox Inc | Formas poliméricas de proteínas H-NOX |
| EP3001813B1 (en) * | 2013-05-13 | 2019-03-27 | Vision Global Holdings Ltd. | Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging |
| US9814759B2 (en) | 2014-07-02 | 2017-11-14 | Cheer Global Ltd. | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment |
| CN107580499A (zh) * | 2015-03-17 | 2018-01-12 | 欧姆尼奥克斯公司 | 通过蛋白质介导的o2递送调节肿瘤免疫性 |
| US9763889B2 (en) | 2015-06-29 | 2017-09-19 | Billion King International Ltd. | Oral delivery system for hemoglobin based oxygen carriers |
| US10052290B2 (en) | 2016-02-04 | 2018-08-21 | Billion King International Ltd. | Enteric-coated hemoglobin multiparticulate for oral delivery of hemoglobin based oxygen carriers |
| CN106421805B (zh) * | 2016-09-14 | 2019-06-04 | 中国人民解放军军事医学科学院野战输血研究所 | 一种右旋糖酐交联血红蛋白氧载体及其制备方法与应用 |
| WO2020080978A2 (ru) * | 2018-10-19 | 2020-04-23 | Рахимджан Ахметджанович РОЗИЕВ | Cпособ получения кровезаменителя для применения в ветеринарии |
| JP2022546993A (ja) * | 2019-08-29 | 2022-11-10 | ビリオン キング インターナショナル リミテッド | チオスクシニル架橋ヘモグロビン類似体、ならびにその使用方法及び調製方法 |
| CN113621055B (zh) * | 2021-08-23 | 2023-05-02 | 山东仙普爱瑞科技股份有限公司 | 一种抗菌和抗病毒的猪血红蛋白β链C端片段、表达该片段的枯草芽孢杆菌、制剂以及应用 |
| EP4402242A4 (en) * | 2021-09-17 | 2025-08-06 | Univ Yale | METHODS, SYSTEMS AND COMPOSITIONS FOR RESTORING AND PRESERVING INTACT ORGANS IN A MAMMAL |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4529719A (en) | 1983-05-04 | 1985-07-16 | Tye Ross W | Modified crosslinked stroma-free tetrameric hemoglobin |
| FR2548671B1 (fr) | 1983-07-07 | 1986-05-02 | Merieux Inst | Procede de preparation de globine a partir d'hemoglobine et globine obtenue par ce procede |
| US4831012A (en) | 1984-03-23 | 1989-05-16 | Baxter International Inc. | Purified hemoglobin solutions and method for making same |
| US4600531A (en) | 1984-06-27 | 1986-07-15 | University Of Iowa Research Foundation | Production of alpha-alpha cross-linked hemoglobins in high yield |
| US4598064A (en) | 1984-06-27 | 1986-07-01 | University Of Iowa Research Foundation | Alpha-alpha cross-linked hemoglobins |
| USRE34271E (en) | 1984-06-27 | 1993-06-01 | University Of Iowa Research Foundation | Production of alpha-alpha cross-linked hemoglobins in high yield |
| JPH0750329B2 (ja) | 1986-06-23 | 1995-05-31 | 富士写真フイルム株式会社 | 画像形成材料 |
| US5753616A (en) | 1986-11-10 | 1998-05-19 | Biopure Corporation | Method for producing a stable polymerized hemoglobin blood-substitute |
| US5955581A (en) | 1986-11-10 | 1999-09-21 | Biopure Corporation | Method for producing a stable polymerized hemoglobin blood-substitute |
| US5084558A (en) | 1987-10-13 | 1992-01-28 | Biopure Corporation | Extra pure semi-synthetic blood substitute |
| CA1312009C (en) | 1986-11-10 | 1992-12-29 | Carl W. Rausch | Extra pure semi-synthetic blood substitute |
| US5189146A (en) | 1987-05-05 | 1993-02-23 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Pasteurizable, freeze-driable hemoglobin-based blood substitute |
| US6150506A (en) * | 1989-05-10 | 2000-11-21 | Baxter Biotech Technology Sarl | Modified hemoglobin-like compounds and methods of purifying same |
| US5439882A (en) | 1989-12-29 | 1995-08-08 | Texas Tech University Health Sciences Center | Blood substitute |
| US5250665A (en) | 1991-05-31 | 1993-10-05 | The University Of Toronto Innovations Foundation | Specifically β-β cross-linked hemoglobins and method of preparation |
| US5344393A (en) | 1992-02-28 | 1994-09-06 | Alliance Pharmaceutical Corp. | Use of synthetic oxygen carriers to facilitate oxygen delivery |
| US6187744B1 (en) | 1992-03-11 | 2001-02-13 | Michael W. Rooney | Methods and compositions for regulating the intravascular flow and oxygenating activity of hemoglobin in a human or animal subject |
| US5399671A (en) * | 1992-11-18 | 1995-03-21 | Kluger; Ronald | Specifically crosslinked hemoglobin with free functionality |
| US5840851A (en) | 1993-07-23 | 1998-11-24 | Plomer; J. Jeffrey | Purification of hemoglobin |
| TW381022B (en) | 1993-08-16 | 2000-02-01 | Hsia Jen Chang | Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute |
| US5840701A (en) | 1993-08-16 | 1998-11-24 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| US5804561A (en) | 1993-08-16 | 1998-09-08 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| US5824781A (en) | 1993-08-16 | 1998-10-20 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| US5817632A (en) | 1993-08-16 | 1998-10-06 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| US5725839A (en) | 1993-08-16 | 1998-03-10 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI |
| US5767089A (en) | 1993-08-16 | 1998-06-16 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| US5807831A (en) | 1993-08-16 | 1998-09-15 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| US5741893A (en) | 1993-08-16 | 1998-04-21 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| US5631219A (en) | 1994-03-08 | 1997-05-20 | Somatogen, Inc. | Method of stimulating hematopoiesis with hemoglobin |
| US6242417B1 (en) | 1994-03-08 | 2001-06-05 | Somatogen, Inc. | Stabilized compositions containing hemoglobin |
| ES2242189T3 (es) | 1994-05-13 | 2005-11-01 | Miltenyi Biotec Gmbh | Columna esteril y apirogena copulada a una proteina con miras a la fijacion y extraccion de sustancias dadas de la sangre. |
| SE9500724D0 (sv) | 1994-06-23 | 1995-02-24 | Pharmacia Ab | Filtrering |
| US5895810A (en) | 1995-03-23 | 1999-04-20 | Biopure Corporation | Stable polymerized hemoglobin and use thereof |
| US6610832B1 (en) | 1995-03-23 | 2003-08-26 | Biopure Corporation | Preserving a hemoglobin blood substitute with a transparent overwrap |
| ES2179188T3 (es) * | 1995-03-23 | 2003-01-16 | Biopure Corp | Sustituto de la sangre a base de hemoglobina polimerizada estable. |
| US6288027B1 (en) | 1995-03-23 | 2001-09-11 | Biopure Corporation | Preserving a hemoglobin blood substitute with a transparent overwrap |
| US5865784A (en) | 1995-06-07 | 1999-02-02 | Alliance Pharmaceutical Corp. | Method of hemodilution facilitated by monitoring oxygenation status |
| US5691453A (en) | 1995-06-07 | 1997-11-25 | Biopure Corporation | Separation of polymerized hemoglobin from unpolymerized hemoglobin on hydroxyapatite using HPLC |
| EP0863918A1 (en) | 1995-11-30 | 1998-09-16 | Somatogen Inc. | Method for control of functionality during cross-linking of hemoglobins |
| ATE247152T1 (de) | 1996-03-21 | 2003-08-15 | Kobusch Sengewald Gmbh & Co Kg | Mehrlagenfolie, verfahren zu ihrer herstellung und ihre verwendung |
| DE69733664T3 (de) | 1996-04-19 | 2011-04-14 | Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles | Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen |
| RU2080865C1 (ru) * | 1996-07-08 | 1997-06-10 | Станислав Людвигович Люблинский | Способ получения гемоглобина |
| EP1015490B1 (en) * | 1997-02-06 | 2004-04-14 | Duke University | No-modified hemoglobins and uses therefor |
| US5814601A (en) | 1997-02-28 | 1998-09-29 | The Regents Of The University Of California | Methods and compositions for optimization of oxygen transport by cell-free systems |
| AU735799C (en) | 1997-02-28 | 2005-04-28 | Regents Of The University Of California, The | Methods and compositions for optimisation of oxygen transport by cell-free systems |
| JP4643004B2 (ja) | 1998-01-06 | 2011-03-02 | シーラス コーポレイション | 生体材料中の病原体不活性化剤をクエンチするための方法 |
| CA2233725A1 (en) * | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| US6894150B1 (en) | 1999-10-01 | 2005-05-17 | Ross Walden Tye | Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin |
| US6747132B2 (en) | 2000-11-29 | 2004-06-08 | Apex Biosciences, Inc. | Methods for the synthesis of a modified hemoglobin solution |
| US6518010B2 (en) | 2001-02-28 | 2003-02-11 | Biopure Corporation | Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier |
| CA2444590C (en) | 2001-04-18 | 2009-12-01 | Robert L. Mcginnis | Stabilized hemoglobin solutions |
| JP4260417B2 (ja) | 2001-05-23 | 2009-04-30 | ノバルティス アクチエンゲゼルシャフト | 溶液を輸送し脱酸素するためのシステム及び方法 |
| US7038016B2 (en) | 2001-08-21 | 2006-05-02 | Apex Bioscience, Inc. | Methods for purification of an activated PEG solution and for the synthesis of a modified hemoglobin solution |
| US20050164915A1 (en) | 2002-04-01 | 2005-07-28 | Sangart, Inc. | Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| US20030153491A1 (en) | 2002-01-11 | 2003-08-14 | Winslow Robert M. | Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin |
| ES2360215T3 (es) | 2002-12-23 | 2011-06-01 | Albert Einstein College Of Medicine Of Yeshiva University | Hemoglobinas pegiladas no hipertensivas y sus procedimientos de preparación. |
| NZ541340A (en) | 2003-01-29 | 2008-04-30 | Northfield Lab | Polymerized hemoglobin solutions having reduced amount of tetramer and method for preparing |
| US7135554B1 (en) * | 2004-01-27 | 2006-11-14 | Biopure Corporation | Method of forming a polymerized hemoglobin solution from stabilized hemoglobin |
| PL1838355T3 (pl) | 2004-10-29 | 2014-01-31 | Cerus Corp | Ulepszone sposoby wygaszania dla procesu inaktywacji czerwonych krwinek |
| WO2007065265A1 (en) | 2005-12-08 | 2007-06-14 | Ronald Kluger | Cross-linking reagents for hemoglobin and hemoglobin products cross-linked therewith |
| US7759306B2 (en) | 2006-05-16 | 2010-07-20 | Simoni Jan S | Methods of treating acute blood loss |
| US7795401B2 (en) | 2006-09-06 | 2010-09-14 | National Chung Cheng University | Modified hemoglobin with allosteric effector conjugated |
| US7504377B2 (en) * | 2006-10-23 | 2009-03-17 | Ikor, Inc. | Nitric oxide-blocked cross-linked tetrameric hemoglobin |
| CN101168565A (zh) * | 2006-10-23 | 2008-04-30 | 爱科有限公司 | 一氧化氮阻断的交联四聚体血红蛋白 |
| US7494974B2 (en) | 2006-10-24 | 2009-02-24 | Ikor, Inc. | Carboxymethylated cross-linked tetrameric hemoglobin |
| US7932356B1 (en) | 2010-06-23 | 2011-04-26 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition |
-
2011
- 2011-04-11 US US13/083,639 patent/US7989593B1/en not_active Expired - Fee Related
- 2011-04-15 SG SG2011062502A patent/SG182237A1/en unknown
- 2011-04-15 PL PL11746429T patent/PL2411025T3/pl unknown
- 2011-04-15 RU RU2011136158/15A patent/RU2475252C1/ru not_active IP Right Cessation
- 2011-04-15 WO PCT/US2011/032594 patent/WO2011149602A1/en not_active Ceased
- 2011-04-15 ES ES11746429.7T patent/ES2527608T3/es active Active
- 2011-04-15 DK DK11746429.7T patent/DK2411025T3/en active
- 2011-04-15 EP EP11746429.7A patent/EP2411025B1/en active Active
- 2011-04-15 KR KR1020117020242A patent/KR101185437B1/ko not_active Expired - Fee Related
- 2011-04-15 PT PT117464297T patent/PT2411025E/pt unknown
- 2011-04-15 CA CA2752943A patent/CA2752943C/en active Active
- 2011-04-15 NZ NZ594915A patent/NZ594915A/xx unknown
- 2011-04-15 CN CN2011800012855A patent/CN102405051B/zh active Active
- 2011-04-15 CN CN201310054976.2A patent/CN103169954B/zh not_active Expired - Fee Related
- 2011-04-15 JP JP2012517937A patent/JP5261806B2/ja active Active
- 2011-04-15 AU AU2011221433A patent/AU2011221433B2/en active Active
- 2011-04-29 TW TW100115051A patent/TWI377947B/zh not_active IP Right Cessation
- 2011-05-24 AR ARP110101773A patent/AR081222A1/es unknown
- 2011-05-24 SA SA111320476A patent/SA111320476B1/ar unknown
-
2012
- 2012-11-20 ZA ZA2012/08726A patent/ZA201208726B/en unknown
-
2015
- 2015-02-04 CY CY20151100114T patent/CY1115986T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1160604A1 (en) | 2012-08-10 |
| TW201141493A (en) | 2011-12-01 |
| KR20110138215A (ko) | 2011-12-26 |
| AR081222A1 (es) | 2012-07-04 |
| WO2011149602A1 (en) | 2011-12-01 |
| ZA201208726B (en) | 2013-09-25 |
| CA2752943C (en) | 2013-10-08 |
| KR101185437B1 (ko) | 2012-10-02 |
| CN103169954B (zh) | 2016-01-20 |
| AU2011221433B2 (en) | 2012-03-29 |
| CN102405051B (zh) | 2013-01-23 |
| CN102405051A (zh) | 2012-04-04 |
| CA2752943A1 (en) | 2011-11-27 |
| HK1166258A1 (en) | 2012-10-26 |
| EP2411025A4 (en) | 2012-11-14 |
| CY1115986T1 (el) | 2017-01-25 |
| WO2011149602A8 (en) | 2012-05-24 |
| NZ594915A (en) | 2013-06-28 |
| AU2011221433A1 (en) | 2011-12-15 |
| PT2411025E (pt) | 2015-02-04 |
| DK2411025T3 (en) | 2015-02-16 |
| PL2411025T3 (pl) | 2015-04-30 |
| US7989593B1 (en) | 2011-08-02 |
| TWI377947B (en) | 2012-12-01 |
| CN103169954A (zh) | 2013-06-26 |
| JP2012526859A (ja) | 2012-11-01 |
| RU2475252C1 (ru) | 2013-02-20 |
| SA111320476B1 (ar) | 2013-07-28 |
| JP5261806B2 (ja) | 2013-08-14 |
| SG182237A1 (en) | 2012-08-30 |
| EP2411025B1 (en) | 2014-11-05 |
| EP2411025A1 (en) | 2012-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2527608T3 (es) | Composición farmacéutica que contiene un vehículo de oxígeno estable a temperatura elevada | |
| ES2404405T3 (es) | Un procedimiento para la preparación de una composición farmacéutica que contiene un portador de oxígeno termoestable | |
| Liao et al. | FasL/Fas pathway is involved in dengue virus induced apoptosis of the vascular endothelial cells | |
| ES2432075T3 (es) | Espray para heridas | |
| JP2010507679A (ja) | 酸化窒素ブロック型架橋四量体ヘモグロビン | |
| Jani et al. | Polyethylene glycol camouflaged earthworm hemoglobin | |
| ES2668674T3 (es) | Procedimiento para retirar hemoglobina no modificada de soluciones de hemoglobina reticulada que incluyen hemoglobina polimérica con aparato de tratamiento térmico de corta duración a altas temperaturas | |
| Baldwin | Modified hemoglobins produce venular interendothelial gaps and albumin leakage in the rat mesentery | |
| Emmons et al. | Intra-erythrocytic location of Colorado tick fever virus | |
| ES2384930T3 (es) | Preparación de inmunoglobulina intravenosa de rendimiento ultra-alto | |
| AR078734A1 (es) | Composiciones, metodos para el tratamiento, y diagnostico de trastornos relacionados con la autoinmunidad y metodos para preparar tales composiciones | |
| Ramzan et al. | Post-dengue fever severe aplastic anemia: a rare association | |
| JP6100252B2 (ja) | 異なる治療用途のための熱安定性酸素キャリアを含有する医薬組成物 | |
| CN101716167A (zh) | 一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用 | |
| Raghupathy et al. | Promising therapies in sickle cell disease | |
| Sotoudeh et al. | Effect of N-acetylcysteine on lung injury induced by skeletal muscle ischemia-reperfusion: histopathological study in rat model | |
| Pohler et al. | Evaluation of the tolerability and immunogenicity of ultraviolet C‐irradiated autologous platelets in a dog model | |
| KR20040032802A (ko) | 뇌졸중 치료를 위한 폴리에틸렌글리콜-헤모글로빈 결합체 | |
| Rampino et al. | Extracellular vesicles derived from mesenchymal stromal cells delivered during hypothermic oxygenated machine perfusion repair ischemic/reperfusion damage of kidneys from extended criteria donors. Biology (Basel). 2022; 11 (3): 350 | |
| Rodrigues et al. | Freshly isolated hepatocyte transplantation in acetaminophen-induced hepatotoxicity model in rats | |
| KRISHNA et al. | A review on artificial blood: a source we need | |
| Ahire et al. | An Overview on Artificial Blood | |
| Prince | The significance of T lymphocytes in transfusion medicine | |
| Brando | Viable lymphocytes in fresh frozen plasma as a potential source of graft-versus-host disease: risks and solutions | |
| Udvardy | Hazardous Clinical Conditions Present Specific Transfusion-Transmitted Disorder Risks and Require Special Attention: Sickle Cell Disease, Transplantation Settings |